Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.97USD
−23.69 MUSD
52.55 MUSD
8.24 M
About Exagen Inc.
Sector
Industry
CEO
John Aballi
Website
Headquarters
Vista
Founded
2002
FIGI
BBG00178FZY1
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of XGN is 2.43 USD — it has decreased by −3.09% in the past 24 hours. Watch Exagen Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Exagen Inc. stocks are traded under the ticker XGN.
XGN stock has fallen by −11.31% compared to the previous week, the month change is a −17.16% fall, over the last year Exagen Inc. has showed a 43.07% increase.
We've gathered analysts' opinions on Exagen Inc. future price: according to them, XGN price has a max estimate of 8.00 USD and a min estimate of 5.00 USD. Watch XGN chart and read a more detailed Exagen Inc. stock forecast: see what analysts think of Exagen Inc. and suggest that you do with its stocks.
XGN stock is 7.85% volatile and has beta coefficient of 0.33. Track Exagen Inc. stock price on the chart and check out the list of the most volatile stocks — is Exagen Inc. there?
Today Exagen Inc. has the market capitalization of 43.64 M, it has decreased by −11.62% over the last week.
Yes, you can track Exagen Inc. financials in yearly and quarterly reports right on TradingView.
Exagen Inc. is going to release the next earnings report on Nov 12, 2024. Keep track of upcoming events with our Earnings Calendar.
XGN earnings for the last quarter are −0.16 USD per share, whereas the estimation was −0.34 USD resulting in a 52.94% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Exagen Inc. earnings.
Exagen Inc. revenue for the last quarter amounts to 15.06 M USD, despite the estimated figure of 13.13 M USD. In the next quarter, revenue is expected to reach 13.57 M USD.
XGN net income for the last quarter is −2.97 M USD, while the quarter before that showed −3.36 M USD of net income which accounts for 11.73% change. Track more Exagen Inc. financial stats to get the full picture.
No, XGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 1, 2024, the company has 179.00 employees. See our rating of the largest employees — is Exagen Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Exagen Inc. EBITDA is −13.81 M USD, and current EBITDA margin is −39.33%. See more stats in Exagen Inc. financial statements.
Like other stocks, XGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Exagen Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Exagen Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Exagen Inc. stock shows the sell signal. See more of Exagen Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.